COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis

References

• JiangF, DengL, ZhangL, CaiY, CheungCW, XiaZ. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545–1549. doi:10.1007/s11606-020-05762-w32133578
   PubMed Web of Science ®Google Scholar
• Jean-S-S, LeeP-I, HsuehP-R. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443. doi:10.1016/j.jmii.2020.03.03432307245
   PubMedGoogle Scholar
• WangB, LaiJ, YanX, JinF, YaoC. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19. Curr Med Res Opin. 2020;36(7):1131–1135. doi:10.1080/03007995.2020.177129432427000
   PubMed Web of Science ®Google Scholar
• WangB, LaiJ, YanX, JinF, YaoC. Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey. Eur J Intern Med. 2020;78:145–146. doi:10.1016/j.ejim.2020.03.01632216996
   PubMed Web of Science ®Google Scholar
• MehraMR, RuschitzkaF, PatelAN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820. doi:10.1016/S0140-6736(20)31324-632511943
   PubMed Web of Science ®Google Scholar
• MehraMR, DesaiSS, KuyS, HenryTD, PatelAN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. N Engl J Med. 2020;382(26):2582. doi:10.1056/NEJMoa2007621
   PubMed Web of Science ®Google Scholar
• ZhangX, YuJ, PanL-Y, JiangH-Y. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacol Res. 2020;158:104927. doi:10.1016/j.phrs.2020.10492732422341
   PubMed Web of Science ®Google Scholar
• MeyerowitzEA, VannierAGL, FriesenMGN, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J. 2020;34(5):6027–6037.32350928
   PubMed Web of Science ®Google Scholar
• TouretF, de LamballerieX. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762. doi:10.1016/j.antiviral.2020.10476232147496
   PubMed Web of Science ®Google Scholar
• RosaSGV, SantosWC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40. doi:10.26633/RPSP.2020.4032256547
   PubMed Web of Science ®Google Scholar
• NasrallahAA, FarranSH, NasrallahZA, et al. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. J Clin Epidemiol. 2020;125:170–178. doi:10.1016/j.jclinepi.2020.06.00532526460
   PubMed Web of Science ®Google Scholar
• BoserupB, McKenneyM, ElkbuliA. An overview of current COVID-19 clinical trials and ethical considerations editorial. Ann Med Surg (Lond). 2020;58:84–86. doi:10.1016/j.amsu.2020.08.04132895612
   PubMed Web of Science ®Google Scholar
• IddaML, SoruD, FlorisM. Overview of the first 6 months of clinical trials for COVID-19 pharmacotherapy: the most studied drugs. Front Public Health. 2020;8:497. doi:10.3389/fpubh.2020.0049732974268
   PubMed Web of Science ®Google Scholar
• KarlsenAPH, WibergS, LaigaardJ, PedersenC, RokampKZ, MathiesenO. A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment. PLoS One. 2020;15(8):e0237903. doi:10.1371/journal.pone.023790332817689
   PubMed Web of Science ®Google Scholar
• Vanden EyndeJJ. COVID-19: a brief overview of the discovery clinical trial. Pharmaceuticals (Basel). 2020;13:4.
   Google Scholar
• SiemieniukRA, BartoszkoJJ, GeL, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. doi:10.1136/bmj.m298032732190
   PubMed Web of Science ®Google Scholar
• HorbyP, MafhamM, LinsellL, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020.
   Web of Science ®Google Scholar
• PanH, PetoR, Abdool KarimQ, et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv. 2020;2020(2010):2015.20209817.
   Google Scholar
• BoulwareDR, PullenMF, BangdiwalaAS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–525. doi:10.1056/NEJMoa201663832492293
   PubMed Web of Science ®Google Scholar
• McMahonJH, UdyA, PelegAY. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020;383(10):992–993.
   PubMed Web of Science ®Google Scholar
• SpinnerCD, GottliebRL, CrinerGJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi:10.1001/jama.2020.1634932821939
   PubMed Web of Science ®Google Scholar
• WangY, ZhangD, DuG, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-932423584
   PubMed Web of Science ®Google Scholar
• BeigelJH, TomashekKM, DoddLE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020.
   Web of Science ®Google Scholar
• SherDJ. An ounce of prevention and a pound of cure: randomized clinical trials of therapeutics against COVID-19 and an assessment of personal protective equipment and distancing. Int J Radiat Oncol Biol Phys. 2020;108(2):333–336. doi:10.1016/j.ijrobp.2020.08.00132890500
   PubMed Web of Science ®Google Scholar
• SharunK, TiwariR, DhamaJ, DhamaK. Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence. Int J Surg. 2020;82:179–181. doi:10.1016/j.ijsu.2020.08.03832896649
   PubMed Web of Science ®Google Scholar
• BrothertonH, UsufE, NadjmB, et al. Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa. Lancet Glob Health. 2020;8(9):e1125–e1126. doi:10.1016/S2214-109X(20)30318-132679038
   PubMed Web of Science ®Google Scholar
• KumariP, RawatK, SahaL. Pipeline pharmacological therapies in clinical trial for COVID-19 pandemic: a recent update. Curr Pharmacol Rep. 2020;1–13.
   Google Scholar
• ZhangY, DingJ, RenS, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. 2020;11(1):207. doi:10.1186/s13287-020-01725-432460839
   PubMed Web of Science ®Google Scholar
• Hamidi AlamdariD, Bagheri MoghaddamA, AminiS, Hamidi AlamdariA, DamsazM, YarahmadiA. The application of a reduced dye used in orthopedics as a novel treatment against Coronavirus (COVID-19): a suggested therapeutic protocol. Arch Bone Jt Surg. 2020;8(Suppl1):291–294.32607398
   PubMedGoogle Scholar
• FitzgeraldJC, WeissSL, MaudeSL, et al. Cytokine release syndrome after chimeric antigen Receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124–e131. doi:10.1097/CCM.000000000000205327632680
   PubMed Web of Science ®Google Scholar
• Abrams-DowneyA, SaabiyeJ, VidaurrazagaM. Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials. Eur Urol Focus. 2020;6(5):1028–1031. doi:10.1016/j.euf.2020.05.01932563675
   PubMedGoogle Scholar
• DastanF, SaffaeiA, HaseliS, et al. Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial. Int Immunopharmacol. 2020;88:106869. doi:10.1016/j.intimp.2020.10686932889241
   PubMed Web of Science ®Google Scholar
• XuX, HanM, LiT, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.200561511732350134
   PubMed Web of Science ®Google Scholar
• LuoP, LiuY, QiuL, LiuX, LiuD, LiJ. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818. doi:10.1002/jmv.2580132253759
   PubMed Web of Science ®Google Scholar
• GuaraldiG, MeschiariM, Cozzi-LepriA, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. doi:10.1016/S2665-9913(20)30173-932835257
   PubMedGoogle Scholar
• AlattarR, IbrahimTBH, ShaarSH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020;92(10):2042–2049. doi:10.1002/jmv.25964
   PubMed Web of Science ®Google Scholar
• HansenJ, BaumA, PascalKE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–1014.32540901
   PubMed Web of Science ®Google Scholar
• BaumA, FultonBO, WlogaE, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–1018.32540904
   PubMed Web of Science ®Google Scholar
• SchlesingerN, FiresteinBL, BrunettiL. Colchicine in COVID-19: an old drug, new use. Curr Pharmacol Rep. 2020;1–9.
   Google Scholar
• SiebenandVS. COVID-19: colchicine in clinical trials. Pharmazeutische Zeitung. 2020;165(21):19.
   Google Scholar
• FeitosaEL, JúniorF, Nery NetoJAO, et al. COVID-19: rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main protease inhibitor. Int J Med Sci. 2020;17(14):2133–2146. doi:10.7150/ijms.4805332922174
   PubMed Web of Science ®Google Scholar
• Acuña-CastroviejoD, EscamesG, FigueiraJC, de la OlivaP, BorobiaAM, Acuña-FernándezC. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020;69(3):e12683. doi:10.1111/jpi.1268332770854
   PubMed Web of Science ®Google Scholar
• AlamdariDH, MoghaddamAB, AminiS, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020;885:173494. doi:10.1016/j.ejphar.2020.17349432828741
   PubMed Web of Science ®Google Scholar
• MerzonE, TworowskiD, GorohovskiA, et al. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 2020;287(17):3693–3702. doi:10.1111/febs.15495
   PubMed Web of Science ®Google Scholar
• CamargoCA Jr, MartineauAR. Vitamin D to prevent COVID-19: recommendations for the design of clinical trials. FEBS J. 2020;287(17):3689–3692. doi:10.1111/febs.15534
   PubMed Web of Science ®Google Scholar
• EmamaulleeJ, BowdishM, YanPY, RodinaV, SherLS. Rapid adaptation of a surgical research unit to conduct clinical trials during the COVID-19 pandemic. J Surg Res. 2020;256:76–82. doi:10.1016/j.jss.2020.06.04932683060
   PubMed Web of Science ®Google Scholar
• YaoC. Clinical trial in China: the status and challenge of data management and statistical analysis. J Evid Based Med. 2018;11(1):3–6. doi:10.1111/jebm.1229529484843
   PubMedGoogle Scholar
• BischofE, WolfeJ, KleinSL. Clinical trials for COVID-19 should include sex as a variable. J Clin Invest. 2020;130(7):3350–3352. doi:10.1172/JCI13930632392184
   PubMed Web of Science ®Google Scholar
• AyoubBM. COVID-19 vaccination clinical trials should consider multiple doses of BCG. Pharmazie. 2020;75(4):159.32295694
   PubMed Web of Science ®Google Scholar
• MathioudakisAG, FallyM, HashadR, KnightS, FeltonT, VestboJ. COVID-19 clinical trials: unraveling a methodological gordian knot. Am J Respir Crit Care Med. 2020;202(5):635–637. doi:10.1164/rccm.202005-1942ED32634026
   PubMed Web of Science ®Google Scholar
• HanZ, WangJ, ZhangK, TangQ. The ethics of COVID-19 clinical trials: new considerations in a controversial area. Integr Med Res. 2020;9(3):100425. doi:10.1016/j.imr.2020.10042532426222
   PubMed Web of Science ®Google Scholar
• SinghAG, ChaturvediP. Clinical trials during COVID-19. Head Neck. 2020;42(7):1516–1518. doi:10.1002/hed.2622332348582
   PubMed Web of Science ®Google Scholar